In a population-based Ontario time-series of 5.3 million tests, weekly rates fell from 228.8 to 105.9 per 100,000 person-weeks during the first lockdown and remained below baseline through early 2022, with outpatient testing hit hardest and a modality shift toward more cardiac CT.

Nested case-control analysis in two prospective birth cohorts DAISY and TEDDY totaling 317 children found 15% higher pre-seroconversion neutrophil-to-lymphocyte ratio and blunted memory-to-naive lymphocyte shifts at seroconversion in those who progressed to type 1 diabetes.

In a phase 1 open-label single-ascending-dose study of 35 adults with HeFH or premature CAD, VERVE-102 reduced LDL cholesterol up to 62% with no dose-limiting toxicity but transient ALT elevations and infusion reactions occurred.

In the open-label Phase 1b Heart-2 single-ascending dose study of 35 adults with HeFH or premature CAD, one IV infusion reduced PCSK9 up to 88% and LDL-C up to 62% with durability to 18 months and no treatment-related serious adverse events.